Literature DB >> 27889900

Unbearable Pruritus After Withdrawal of (Levo)cetirizine.

Corine Ekhart1, Petra van der Horst2, Florence van Hunsel2.   

Abstract

Twelve cases of unbearable pruritus several days after withdrawal of (levo)cetirizine were reported to the Netherlands Pharmacovigilance Centre Lareb. Eleven reports concerned women and one report concerned a man, aged 19-58 years. These patients had been using these antihistamines continuously for months or years. They had tried to stop using antihistamines on several occasions but felt unable to withdraw the drug because of the unbearable maddening itch. Finally, slowly tapering the drug or using a short course of corticosteroids helped to withdraw (levo)cetirizine. The Naranjo assessment score ranged from two to four for all the cases, indicating a possible relationship.

Entities:  

Year:  2016        PMID: 27889900      PMCID: PMC5124431          DOI: 10.1007/s40800-016-0041-9

Source DB:  PubMed          Journal:  Drug Saf Case Rep        ISSN: 2199-1162


Key Points

Introduction

Allergic rhinitis is an inflammatory immunoglobulin E-mediated disease with symptoms of sneezing, nasal pruritus, nasal congestion and nasal discharge. Triggering allergens include seasonal pollens and moulds, as well as dust mites and pets. Allergic rhinitis can be seasonal or year round, with symptoms being intermittent or persistent [1]. Sensitisation to inhaled allergens begins during the first year of life. The prevalence of allergic rhinitis peaks in the second to fourth decades of life and then gradually diminishes [2]. Allergic rhinitis is a common disease, with a prevalence estimated between 10 and 30% of the population [3]. Treatment options include H1-antihistamines, intranasal glucocorticoids, leukotriene-receptor antagonists and allergen immunotherapy [2]. Oral antihistamines have been in use since 1940. These agents are effective for the relief of symptoms including rhinorrhoea, sneezing, itching, nasal blockage as well as associated ocular complaints. Oral antihistamines can be broadly categorised as first- or second-generation antihistamines. The first-generation antihistamines have side effects such as sedation and mucosal dryness, which limit their use. Second-generation antihistamines are highly selective for the H1 receptor and have limited penetration of the central nervous system. Cetirizine and levocetirizine belong to the second-generation antihistamines. Levocetirizine is the active R-enantiomer of cetirizine. The advantages of treatment with oral antihistamines include a rapid onset of action, once-daily dosing, maintenance of effectiveness with regular use and the availability of some drugs without a prescription. Maximum benefit is seen with continuous use, but in patients with intermittent symptoms use on an as-needed basis can provide significant symptom relief [1]. In the period from October 1989 to June 2016, the Netherlands Pharmacovigilance Centre Lareb received 12 reports of unbearable pruritus after withdrawal of cetirizine or levocetirizine. Four reports were reported by healthcare professionals and eight reports were reported by consumers. Striking in these reports is the occurrence of a maddening generalised itch after withdrawal of the antihistamine, which is reported to be different to the complaints that the antihistamines were used for in the first place.

Case Reports

Lareb received 12 reports of generalised pruritus after withdrawal of (levo)cetirizine (Table 1). The patients described pruritus without any other symptoms such as rashes or urticaria. The reports concerned 11 women and one man with a median age of 39 years (range 19–58 years). The pruritus occurred 1–3 days after withdrawal of long-term use of (levo)cetirizine. The patients had been using (levo)cetirizine continuously for months or years. Nine patients reported that they tried to stop using (levo)cetirizine several times but were not able to withdraw the drug because of the unbearable itch. One patient reported that a gradual reduction in dose helped and that after several weeks, the itching slowly receded and eventually disappeared. Another patient used a short course of corticosteroids. Five patients reported the use of concomitant medication. The concomitant medication was started years before the onset of the pruritus (1–13 years). The following case report (case 11 in Table 1), with a report date of 24 February, 2016, is representative of the cases reported to Lareb.
Table 1

Reports of pruritus after withdrawal of (levo)cetirizine received at Lareb

Case numberReporterSexAge (years)DrugDose (mg/day)IndicationUseTime to onset after withdrawalPositive re-challengeConcomitant medicationNaranjo score
1General practitionerF37Cetirizine20NRChronic useNRNRIpratropium, budesonide nasal spray3
2General practitionerF48Cetirizine10Hay feverMonths1.5 daysYes4
3General practitionerF30Cetirizine10Dust mite allergyYears1.5 daysYes4
4PharmacistF40Levocetirizine5NR4 monthsDaysNRFluticasone inhaler, fusidic acid eye drops, desogestrel3
5ConsumerF51Levocetirizine10Hay fever6 monthsDaysYesMometasone nasal spray3
6ConsumerF35Levocetirizine5Hay fever9 years1 dayYes3
7ConsumerF25Levocetirizine5Urticaria10 years3 daysYesFluoxetine, ethinyl estradiol/levonorgestrel3
8ConsumerF19Cetirizine20AllergyMonths3 daysNR2
9ConsumerF58Levocetirizine5Hay fever2 years1 dayYesCalcium/colecalciferol3
10ConsumerF40Cetirizine10Hay fever1 year1 dayYes3
11ConsumerF20Levocetirizine5Hay fever2 years1 dayYes3
12ConsumerM51Cetirizine10Hay fever5 monthsDaysYes3

F female, M male, NR not reported

Reports of pruritus after withdrawal of (levo)cetirizine received at Lareb F female, M male, NR not reported A 20-year-old woman had been using levocetirizine for hay fever for 2 years. Twenty-six hours after withdrawal she experienced pruritus. It started as a burning itch across the hands. The pruritus aggravated gradually across her head and was generalised after 2 days. It was unbearable, she could not sleep and was unable to go to work. In the past, she had tried to stop using levocetirizine several times, but every time there was more than 24 h between the intake of tablets, she would experience pruritus. The longer the period between the intake between two tablets, the worse the pruritus became. When she took levocetirizine, the pruritus would disappear within 30 min. Therefore, she felt unable to withdraw levocetirizine. Ultimately, she was treated with prednisolone for 1 week and is recovering 3 weeks after withdrawal. The Naranjo causality score for this case was three.

Discussion

Pruritus is a common symptom that is experienced by all humans at some point in life. It occurs in a diverse range of skin diseases and may affect the skin, mucous membranes and cornea. The frequent occurrence of pruritus is supported by the results of epidemiological studies that found the prevalence of pruritus in the general population was approximately 8% [4]. Unbearable itch after withdrawal of antihistamines is not a common phenomenon. A PubMed search revealed no published reports of this association. However, there has been extensive discussion about the occurrence of pruritus after withdrawal of (levo)cetirizine on several patient forums and blogs [5, 6]. Antihistamines are used for the treatment of pruritus and therefore one would expect that withdrawal of antihistamines leads to the same symptoms for what the antihistamines were described. However, the patients in the cases reported to the Netherlands Pharmacovigilance Centre Lareb describe the generalised unbearable itch as a completely different itch for which (levo)cetirizine was described. In the majority of cases, the indication for use was hay fever. Many internal diseases may present with itching symptoms. Pruritus is a frequent manifestation in patients with liver diseases and intra- or post-hepatic cholestasis, a sign of chronic renal insufficiency and a number of haematological diseases such as polycythaemia vera [7]. There is no indication in the reported cases that patients experienced any of these underlying diseases because there are no other reactions reported besides pruritus and no concomitant medication that would suggest the presence of such illnesses. Unfortunately, no laboratory values were provided in the reports to exclude underlying diseases, but there were four reports that were medically confirmed and these healthcare providers did not mention any other causes for the pruritus. Although (levo)cetirizine has been reported to cause nephritis or hepatotoxicity [8, 9], this is an unlikely cause of the pruritus in these cases as the reaction only started after withdrawal of the drug and there were a number of patients with ‘positive re-challenges’. Pruritus can be a side effect of a variety of drugs, such as morphine, opioids, angiotensin converting enzyme inhibitors, analgesics, vitamin A, contrast media, gold, chloroquine and sulphonamides [10]. However, all the concomitant medications that were reported had already been used years prior to the reaction and the time relation strongly links the pruritus to the withdrawal of (levo)cetirizine. The Naranjo causality score ranged from two to four for all the cases. This is a relatively low score. However, the Naranjo causality score is not really suited for withdrawal reactions [11]. How long-term treatment with (levo)cetirizine may cause this withdrawal reaction is not known. H1 receptors mediate allergy in peripheral tissues and histaminergic neurotransmission in the central nervous system. The H1 receptor (H1R) gene is upregulated in patients with pollinosis. Its expression level is highly correlated with allergic symptom severity. Antihistamines are widely used as allergy treatments because they inhibit histamine signalling by blocking H1R or suppressing H1R signalling as inverse agonists [12]. Long-term treatment with antihistamines can decrease H1R gene expression to the basal level [13]. It is hypothesised that after stopping long-term treatment, H1R blockade disappears relatively fast (the half-life of (levo)cetirizine is 6–10 h). In the presence of histamine, this can lead to occupancy of the H1R and because the number of H1R was down-regulated owing to long-term treatment, a relatively high percentage of H1R will be occupied with histamine, possibly resulting in itch. Short-term use will probably not lead to these symptoms because down-regulation of H1R has not been achieved in that time. It is remarkable that the patients reported at Lareb only experienced itch and no other symptoms induced by occupancy of the H1 receptor. (Levo)cetirizine is a commonly prescribed drug in the Netherlands. Around 430,000 patients each year are prescribed (levo)cetirizine [14]. Levocetirizine and cetirizine are the only antihistamines in the Lareb database of which there are reports about this withdrawal reaction. There are no reports of unbearable itch after withdrawal of other antihistamines.

Conclusion

Based on the cases reported to the Netherlands Pharmacovigilance Centre Lareb, we suggest a causal relation between withdrawal of (levo)cetirizine and the occurrence of unbearable pruritus. The Naranjo assessment score ranged from two to four for all the cases, indicating a possible relationship. Healthcare professionals should be aware that in some patients this reaction can occur. Gradually reducing the dose of the (levo)cetirizine or a short course of corticosteroids might help in withdrawing the antihistamine.
(Levo)cetirizine is widely used in the treatment of allergic rhinitis and is tolerated well.
However, generalised pruritus after withdrawal can occur, making patients feel unable to stop using the antihistamine.
Gradually reducing the dose of the (levo)cetirizine or a short course of corticosteroids might help in withdrawing the antihistamine.
  10 in total

1.  Levocetirizine induced hepatotoxicity in a patient with chronic urticaria.

Authors:  Fuat Ekiz; Ilhami Yüksel; Ozlem Ekiz; Sahin Coban; Omer Basar; Osman Yüksel
Journal:  Ann Hepatol       Date:  2011 Apr-Jun       Impact factor: 2.400

2.  Acute interstitial nephritis secondary to long-term use of cetirizine for the treatment of urticaria pigmentosa.

Authors:  R Raghavendran; A R Shipman; G Langman; S Vijayan; S D Orpin
Journal:  Clin Exp Dermatol       Date:  2012-10-22       Impact factor: 3.470

Review 3.  Clinical practice. Allergic rhinitis.

Authors:  Lisa M Wheatley; Alkis Togias
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

4.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

5.  Suplatast tosilate alleviates nasal symptoms through the suppression of nuclear factor of activated T-cells-mediated IL-9 gene expression in toluene-2,4-diisocyanate-sensitized rats.

Authors:  Hiroyuki Mizuguchi; Naoki Orimoto; Takuya Kadota; Takahiro Kominami; Asish K Das; Akiho Sawada; Misaki Tamada; Kohei Miyagi; Tsubasa Adachi; Mayumi Matsumoto; Tomoya Kosaka; Yoshiaki Kitamura; Noriaki Takeda; Hiroyuki Fukui
Journal:  J Pharmacol Sci       Date:  2016-01-06       Impact factor: 3.337

6.  Self-reported skin morbidity among adults: associations with quality of life and general health in a Norwegian survey.

Authors:  Florence Dalgard; Ake Svensson; Jan Øivind Holm; Johanne Sundby
Journal:  J Investig Dermatol Symp Proc       Date:  2004-03

7.  Clinical practice guideline: Allergic rhinitis.

Authors:  Michael D Seidman; Richard K Gurgel; Sandra Y Lin; Seth R Schwartz; Fuad M Baroody; James R Bonner; Douglas E Dawson; Mark S Dykewicz; Jesse M Hackell; Joseph K Han; Stacey L Ishman; Helene J Krouse; Sonya Malekzadeh; James Whit W Mims; Folashade S Omole; William D Reddy; Dana V Wallace; Sandra A Walsh; Barbara E Warren; Meghan N Wilson; Lorraine C Nnacheta
Journal:  Otolaryngol Head Neck Surg       Date:  2015-02       Impact factor: 3.497

8.  Effects of antihistamine on up-regulation of histamine H1 receptor mRNA in the nasal mucosa of patients with pollinosis induced by controlled cedar pollen challenge in an environmental exposure unit.

Authors:  Yoshiaki Kitamura; Hideyuki Nakagawa; Tatsuya Fujii; Takema Sakoda; Tadao Enomoto; Hiroyuki Mizuguchi; Hiroyuki Fukui; Noriaki Takeda
Journal:  J Pharmacol Sci       Date:  2015-10-30       Impact factor: 3.337

9.  Pruritus in certain internal diseases.

Authors:  D Yonova
Journal:  Hippokratia       Date:  2007-04       Impact factor: 0.471

Review 10.  Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine.

Authors:  Xue Yan Wang; Margaret Lim-Jurado; Narayanan Prepageran; Pongsakorn Tantilipikorn; De Yun Wang
Journal:  Ther Clin Risk Manag       Date:  2016-04-13       Impact factor: 2.423

  10 in total
  1 in total

1.  Pruritus after discontinuation of cetirizine.

Authors:  Amy H Chung; Lois La Grenade; Lisa M Harinstein
Journal:  Ther Adv Drug Saf       Date:  2019-07-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.